ReviewCancers2021
Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma.BJC reports · 2026Article
- Integrative single-cell RNA-seq and transcriptomic analysis uncovers cellular heterogeneity and immunotherapy resistance mechanisms in colorectal cancer.Discover oncology · 2026Article
- Structural Elucidation and Covalent Modulation of the Autorepressed Orphan Nuclear Receptor NR2F6.ACS chemical biology · 2025Article
- NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosis.PloS one · 2025Article
- Roles of the NR2F Family in the Development, Disease, and Cancer of the Lung.Journal of developmental biology · 2024Review
- Concerted regulation of skeletal muscle metabolism and contractile properties by the orphan nuclear receptor Nr2f6.Journal of cachexia, sarcopenia and muscle · 2024Article
- Predicting feature genes correlated with immune infiltration in patients with abdominal aortic aneurysm based on machine learning algorithms.Scientific reports · 2024Article
- Delineating the role of nuclear receptors in colorectal cancer, a focused review.Discover oncology · 2024Review
- Application of hydrogels in cancer immunotherapy: a bibliometric analysis.Frontiers in immunology · 2024Article
- Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.Vaccines · 2023Review
- Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients.Journal of cancer research and clinical oncology · 2023Article
- Regulation of PD-L1 Expression by Nuclear Receptors.International journal of molecular sciences · 2023Review
- NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.Frontiers in immunology · 2023Article
- Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Additional therapeutic targets suitable for boosting anti-tumor effector responses have been found inside effector CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.